GlassScriptPhysician profile
Kourtney Bell King
NPI 1174020861
$7,964.26
in general payments reported to CMS, 2019-2025
10 companies · $7,090 in 2025
The $7,090 reported for 2025 was more than what 91% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $269 · 2023: $383 · 2024: $223 · 2025: $7,090.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $5,558 · Travel and Lodging: $1,305 · Food and Beverage: $832.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $5,557.99 |
| Travel and Lodging | $1,305.01 |
| Food and Beverage | $832.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $6,805.01 | 2025 | |
| Abbvie INC. | $273.19 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $262.86 | 2022-2025 | Ofev |
| Insmed, INC. | $261.92 | 2023-2024 | Arikayce |
| Janssen Pharmaceuticals, INC | $123.81 | 2022 | |
| Pulmonx Corporation | $108.50 | 2023-2024 | Zephyr Endobronchial Valve, Chartis Catheter, Pulmonx Chartis Tablet Console |
| Olympus America INC. | $45.76 | 2025 | |
| United Therapeutics Corporation | $29.33 | 2023 | Tyvaso |
| Alcresta Therapeutics, INC. | $28.61 | 2025 | Relizorb |
| Astellas Pharma US INC | $25.27 | 2024 | Cresemba |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kourtney King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.